Bayer is paying $17.5 million upfront to US biotech Arvinas, tapping into a protein-targeting platform to seek new drugs for cardiovascular and gynaecological diseases and cancer, as well as agricultural products. The pharmaceutical end of the all...
Original Article: Bayer buys into Arvinas protein degrader discovery platform